PT003 MDI Cardiovascular Safety Study

Trial Identifier: PT003003
Sponsor: Pearl Therapeutics, Inc.
NCTID:: NCT01349803
Start Date: May 2011
Primary Completion Date: November 2011
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia, New South Wales Glebe, New South Wales, Australia
Australia, Queensland Caboolture, Queensland, Australia
Australia, South Australia Dawpark, South Australia, Australia
Australia, South Australia Toorak Gardens, South Australia, Australia
Australia, Victoria Heidelberg, Victoria, Australia
Australia, Western Australia Nedlands, Western Australia, Australia
New Zealand, Dunedin Caversham, Dunedin, New Zealand
New Zealand, Hamilton Private Bag, Hamilton, New Zealand
New Zealand, North Island Tauranga, North Island, New Zealand
New Zealand, Wellington Newtown, Wellington, New Zealand
USA, Arizona Glendale, Arizona, USA
USA, California Fullerton, California, USA
USA, California Los Angeles, California, USA
USA, California San Diego, California, USA
USA, Florida Pensacola, Florida, USA
USA, Louisiana Lafayette, Louisiana, USA
USA, Massachusetts North Dartmouth, Massachusetts, USA
USA, Michigan Livonia, Michigan, USA
USA, Oregon Medford, Oregon, USA
USA, Texas San Antonio, Texas, USA